Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines Lundbeck has submitted a new drug application for Vyepti® in Japan, China, and South Korea, aiming to enhance treatment options for migraine sufferers.

Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines #Japan #Lundbeck #Valby #Vyepti #Eptinezumab

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/LE6FP

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/HStkM

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More Lundbeck showcases significant migraine data at the 2025 International Headache Congress, highlighting the long-term effectiveness of Eptinezumab in chronic migraine patients, aiming to improve lives.

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More #United_States #São_Paulo #Lundbeck #Vyepti #Eptinezumab

Lundbeck Unveils Groundbreaking Migraine Data at 2025 IHC, Highlighting Vyepti's Long-Term Effectiveness Lundbeck presents compelling data on Vyepti®'s long-term effectiveness in migraine prevention at the 2025 IHC, showcasing significant patient benefits.

Lundbeck Unveils Groundbreaking Migraine Data at 2025 IHC, Highlighting Vyepti's Long-Term Effectiveness #São_Paulo #Denmark #Lundbeck #Vyepti #Eptinezumab

New Eptinezumab Trial Results Show Promise for Severe Migraine Treatment The phase IV RESOLUTION trial reveals that eptinezumab significantly reduces monthly migraine days in chronic migraine patients, paving a new treatment path.

New Eptinezumab Trial Results Show Promise for Severe Migraine Treatment #Denmark #Chronic_Migraine #Valby #Eptinezumab #RESOLUTION_Trial

Eptinezumab Shows Significant Efficacy for Severe Migraine Patients in RESOLUTION Trial The phase IV RESOLUTION trial reveals that eptinezumab greatly reduces migraine days in patients with chronic migraine, providing new hope for severe migraine sufferers.

Eptinezumab Shows Significant Efficacy for Severe Migraine Patients in RESOLUTION Trial #Denmark #Valby #Vyepti #Eptinezumab #RESOLUTION_Trial

Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results A recent trial shows that Eptinezumab effectively reduces monthly migraine days in the Asian population, crucial in addressing unmet healthcare needs.

Eptinezumab Efficacy Confirmed in Asian Chronic Migraine Patients from Phase III Trial Results #Denmark #Valby #Vyepti #Eptinezumab #SUNRISE_Trial

New Phase III Trial Results Showcase Efficacy of Vyepti® for Chronic Migraine in Asian Patients The latest findings from the SUNRISE trial reveal significant improvements in chronic migraine treatment efficacy for the Asian population using Vyepti® (eptinezumab).

New Phase III Trial Results Showcase Efficacy of Vyepti® for Chronic Migraine in Asian Patients #Denmark #Chronic_Migraine #Valby #Vyepti #Eptinezumab

<em>Headache: The Journal of Head and Face Pain</em> | AHS Journal | Wiley Online Library There are limited treatment options to prevent migraine in young people (aged 6–17 years). Eptinezumab is proven to prevent migraine in adults, and in this open-label trial, we gave eptinezumab to yo...

The #phase1 #pharmacokinetic #trial on the use of #eptinezumab in #children and #adolescents with #migraine is now published. Recommends weight-based dosing. @headachejournal.bsky.social headachejournal.onlinelibrary.wiley.com/doi/pdf/10.1...

Open Access:
A recent pharmacokinetics & safety study of #eptinezumab in children & adolescents with #migraine supports the use of weight-based dosing & finds the drug generally well tolerated w no new safety signals
headachejournal.onlinelibrary.wiley.com/share/KG8U6B...
Andrew Hershey MD PhD et al

<em>Headache: The Journal of Head and Face Pain</em> | AHS Journal | Wiley Online Library Calcitonin gene-related peptide (CGRP) is a potent cerebral vasodilator and part of the trigeminal migraine cascade. Newer migraine therapies target CGRP signaling for both acute and preventative man...

Open Access:
A Kuczynski & W Kingston share 1st cases of #galcanezumab use in someone w #MELAS & #eptinezumab in an individual w #CADASIL, suggesting #CGRP driven processes driving #migraine even in those w genetically determined disease
headachejournal.onlinelibrary.wiley.com/doi/full/10....